EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Interpretable multimodal network analysis of lipid‐lowering therapies

Daniele Dall'Olio, Matteo Pedrelli, Claudia Sala, Francesca Grassi, Ruisheng Wang, Osman Ahmed, Carsten O. Daub, Daniel Remondini, Gastone Castellani, Davide Gentilini, Chiara Pirazzini, Paolo Garagnani, Enrico Petrillo, Matteo Bersanelli, Elliott M. Antman, Joseph Loscalzo, Paolo Parini

British Journal of Pharmacology · 2026-11-10

DOI: 10.1111/bph.70730 ↗
AbstractBibliografische Angaben

Abstract

Background and Purpose Multimodal integration of clinical and omics data could clarify the hepatic mechanisms of lipid‐lowering therapies, but interpretable methods for heterogeneous data remain limited. The objective was to apply interpretable multimodal networks (IMNs), a topology‐aware framework that condenses heterogeneous omics and clinical data into compact, cross‐modal modules, to characterize treatment‐specific hepatic responses to simvastatin and ezetimibe. Experimental Approach In the Stockholm Study, patients scheduled for cholecystectomy were randomized for 4 weeks to simvastatin, ezetimibe, their combination or placebo. We integrated liver transcriptomics and DNA methylation with plasma/bile biochemistry, including lipoprotein functionality, on the human protein–protein interactome to build treatment‐specific IMNs and evaluated selected network‐derived predictions in a human hepatocyte‐like model (SOAT2‐only‐HepG2). Key Results IMNs reduced dimensionality while preserving network topology, producing distinct molecular signatures for simvastatin, ezetimibe and combination therapy that mapped to different biological processes; the placebo network was less multimodal and more fragmented. IMNs highlighted apolipoprotein‐centred modules and predicted drug effects on APOA2, PPARA and PTPRS, linked to plasma C‐peptide. In SOAT2‐only‐HepG2 cells, selected predictions were supported experimentally, including APOA2 induction and ezetimibe‐associated PTPRS upregulation. Conclusions and Implications IMNs provide a practical, interactome‐based route from multimodal patient data to focused, testable hypotheses about lipid‐lowering therapies, yielding compact features suitable for downstream predictive modelling while retaining biological interpretability.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →